Virtual screening analysis of natural flavonoids as trimethylamine (TMA)‐lyase inhibitors for coronary heart disease. Issue 12 (9th August 2022)

• Record Type: Journal Article
• Authors: Zhou, Peng; Zhao, Xiao‐Ni; Ma, Yao‐Yao; Tang, Tong‐Juan; Wang, Shu‐Shu; Wang, Liang; Huang, Jin‐Ling
• Is Part Of: Journal of food biochemistry. Volume 46:Issue 12(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-09
• Subjects: flavonoids -- trimethylamine‐lyase -- TMAO -- coronary heart disease -- molecular docking; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Biochemistry -- Periodicals; 664.024
• DOI: 10.1111/jfbc.14376
• Languages: English
• ISSNs: 0145-8884

Abstract

Abstract: Coronary heart disease (CHD) is defined by atherosclerosis, which can result in stenosis or blockage of the arterial cavity, leading to ischemic cardiac diseases such as angina and myocardial infarction. Accumulating evidence indicates that the gut microbiota plays a vital role in the beginning and progression of CHD. The gut microbial metabolite, trimethylamine‐N‐oxide (TMAO), is intimately linked to the pathophysiology of CHD. TMAO is formed when trimethylamine (TMA) is converted by flavin‐containing monooxygenases in the hepatocytes. Therefore, inhibition of TMA production is essential to reduce TMAO levels. Flavonoids may reduce the risk of death from cardiovascular disease. In this article, we reviewed and evaluated twenty‐two flavonoids for the therapy of CHD based on their inhibition of TMA‐lyase by molecular docking. Docking results revealed that baicalein, fisetin, acacetin, and myricetin in flavonoid aglycones, and baicalin, naringin, and hesperidin in flavonoid glycosides had a good binding effect with TMA‐lyase. This indicates that these chemicals were the most active and could be used as lead compounds for structural modification in the future. Practical applications: Flavonoids are a large class of polyphenolic compounds found in fruits, vegetables, flowers, tea, and herbal medicines, which are inexorably metabolized and transformed into bioactive metabolites by α‐rhamnosidase, β‐glucuronidase, β‐glucosidase, and nitroreductase produced by the gut microbiota, which plays a beneficial role in the prevention and treatment of cardiovascular diseases. Because flavonoids protect the cardiovascular system and regulate the gut microbiota, and the gut microbiota is directly connected to TMAO, thus, reducing TMAO levels involves blocking the transition of TMA to TMAO, which may be performed by reducing TMA synthesis. Molecular docking results found that baicalein, fisetin, acacetin, and myricetin in flavonoid aglycones, and baicalin, naringin, and hesperidin in flavonoid glycosides had good binding effects on TMA‐lyase, which were the most active and could be used as lead compounds for structural modification. Abstract : The TMA/TMAO pathway represents one of many microbe‐dependent pathways that will ultimately be linked to CHD pathogenesis Molecular docking results found that baicalein, fisetin, acacetin, and myricetin in flavonoid aglycones, and baicalin, naringin and hesperidin in flavonoid glycosides had good binding effects on TMA‐lyase, which were the most active and could be used as lead compounds for structural modification.